tasly 1 billion yuan for private offering

tasly (600535) notice, the company intends to be not less than 26.73 yuan/share price, to not more than 10 of the specific object of the non-public issue of 20 million to 40 million shares, the funds raised to seven construction and technical transformation projects, the total investment amount of 1.069 billion yuan, all to raise capital investment. According to the announcement, the company plans to invest seven projects including the compound Danshen drop pill expansion project, the modern Chinese Medicine solid dosage expansion construction project, the tasly Modern Chinese Medicine Resources Limited Company GMP Technical Transformation Project, the tasly Research and Development Center construction project, the modern Logistics distribution Center construction project, 37 medicinal material reserve and the planting base construction and modern Chinese Medicine industry chain Information System construction project.　　Among them, the compound Danshen drop pill expansion project plans to invest 305 million yuan, the modern Chinese Medicine solid preparation expansion construction project proposed invests 254 million yuan. The company said that the existing drop pill dosage form production line design capacity of 9.6 billion pills per year, compound danshen dripping pill products since the listing has maintained a faster sales growth, the company's actual production capacity than the original design capacity has been a certain degree of improvement, but still can not meet the company's future rapid development needs. The company's compound danshen dripping pill and the Qi ginseng Yiqi dripping pill future development space is broad. The construction period of the expansion project is 18 months, from October 2010 to March 2012.　　The announcement said that the project was built up to the postpartum, the annual average operating income is expected to be 954.593 million yuan, payback period of 4.14 years, after-tax financial internal rate of return of 42.93%. The construction project of modern solid preparation of Chinese herbal medicine is the expansion construction project of the company's Serum Brain granule (pill) and silibinin capsules solid preparation, the project construction period is 15 months, from October 2010 to December 2011.　　Project fully up to the postpartum average annual expected to increase the operating income of 977.55 million yuan, investment recovery period of 5.15 years, after-tax financial internal rate of return of 31.1%. Company said that the general plan of the new medical reform was formally launched in April 2009, the National Basic Drug system was formally implemented, the advancement of the new medical reform system and the implementation of the policy provided a rare historical opportunity for the development of pharmaceutical enterprises. At the same time, the fierce competition in the pharmaceutical market also makes it necessary to take effective measures　　Further expand the product scale and maintain the market leading position. 2009, the company's business has maintained a steady development, the company achieved total operating income of 399,264 530,000 yuan, an increase of 16.26%, net profit (attributable to the parent company shareholders) 31,670 630,000 Yuan, the increase of 23.77%, the pharmaceutical industry to achieve sales revenue 162,483.250,000 yuan , an increase of 10.89%.